{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:08:49Z","timestamp":1791198529881,"version":"4.1.0"},"reference-count":158,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Research Reviews"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.brainresrev.2008.12.001","type":"journal-article","created":{"date-parts":[[2008,12,17]],"date-time":"2008-12-17T13:12:20Z","timestamp":1229519540000},"page":"410-431","source":"Crossref","is-referenced-by-count":60,"title":["The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease"],"prefix":"10.1016","volume":"59","author":[{"given":"Joana M.","family":"Gil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Cristina","family":"Rego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainresrev.2008.12.001_bib1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nbdi.2001.0406","article-title":"Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease","volume":"8","author":"Andreassen","year":"2001","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib2","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1097\/00001756-200110290-00044","article-title":"Lipoic acid improves survival in transgenic mouse models of Huntington's disease","volume":"12","author":"Andreassen","year":"2001","journal-title":"NeuroReport"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ana.1085","article-title":"Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease","volume":"50","author":"Andreassen","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1006\/nbdi.2002.0562","article-title":"Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression","volume":"11","author":"Andreassen","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mcn.2008.04.007","article-title":"CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6\/2 mice","volume":"39","author":"Apostol","year":"2008","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0531-5565(01)00147-4","article-title":"Effect of DL-alpha-lipoic acid on glutathione metabolic enzymes in aged rats","volume":"37","author":"Arivazhagan","year":"2001","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuron.2005.06.005","article-title":"p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease","volume":"47","author":"Bae","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib8","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1091\/mbc.E05-07-0607","article-title":"Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin","volume":"17","author":"Benchoua","year":"2006","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib9","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1523\/JNEUROSCI.21-17-06718.2001","article-title":"Adenoviral brain-derived neurotrophic factor induces both neostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain","volume":"21","author":"Benraiss","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1517\/14740338.3.6.525","article-title":"The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis","volume":"3","author":"Bensimon","year":"2004","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/hmg\/ddi053","article-title":"The R6\/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient \u03b2-cell mass","volume":"14","author":"Bj\u00f6rkqvist","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib12","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/hmg\/ddl094","article-title":"Progressive alterations in the hypothalamic\u2013pituitary\u2013adrenal axis in the R6\/2 transgenic mouse model of Huntington's disease","volume":"15","author":"Bj\u00f6rkqvist","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib13","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1037\/0735-7044.117.6.1233","article-title":"Exploratory activity and fear conditioning abnormalities develop early in R6\/2 Huntington's disease transgenic mice","volume":"117","author":"Bolivar","year":"2003","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib158","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.brainres.2004.01.021","article-title":"Early exploratory behavior abnormalities in R6\/1 Huntington's disease transgenic mice","volume":"1005","author":"Bolivar","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004850-200411000-00004","article-title":"Neuroprotection in Huntington's disease: a 2-year study on minocycline","volume":"19","author":"Bonelli","year":"2004","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib15","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1172\/JCI27607","article-title":"Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase","volume":"116","author":"Borrell-Pag\u00e8s","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib16","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1523\/JNEUROSCI.1197-04.2004","article-title":"Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease","volume":"24","author":"Canals","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib17","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1523\/JNEUROSCI.19-08-03248.1999","article-title":"Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation","volume":"19","author":"Carter","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/1531-8257(200009)15:5<925::AID-MDS1025>3.0.CO;2-Z","article-title":"Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene","volume":"15","author":"Carter","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0166-2236(00)01609-X","article-title":"Transcriptional dysregulation in Huntington's disease","volume":"23","author":"Cha","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib20","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1073\/pnas.95.11.6480","article-title":"Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene","volume":"95","author":"Cha","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/80538","article-title":"Minocycline inhibits caspase-1 and caspase-3 expression and delaus mortality in a transgenic mouse model of Huntington disease","volume":"6","author":"Chen","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib22","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1172\/JCI31778","article-title":"Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease","volume":"117","author":"Cho","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib23","doi-asserted-by":"crossref","first-page":"16685","DOI":"10.1073\/pnas.0707842104","article-title":"A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6\/2 transgenic mouse","volume":"104","author":"Chopra","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1471-4159.2005.03029.x","article-title":"CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model","volume":"93","author":"Chou","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0306-4522(01)00409-2","article-title":"Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease","volume":"109","author":"Clifford","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcn.2008.04.012","article-title":"Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347","volume":"39","author":"Conforti","year":"2008","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib28","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","article-title":"Therapeutic effects of cystamine in a murine model of Huntington's disease","volume":"22","author":"Dedeoglu","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib29","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1046\/j.1471-4159.2003.01706.x","article-title":"Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice","volume":"85","author":"Dedeoglu","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib30","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/brain\/114.4.1953","article-title":"Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia","volume":"114","author":"Dexter","year":"1991","journal-title":"Brain"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib31","first-page":"485","article-title":"The novel substituted pyrimidine, KP544, reduces motor deficits in the R6\/2 transgenic mouse model of Huntington's disease","volume":"25","author":"Dey","year":"2007","journal-title":"Restor. Neurol. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib32","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib33","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1212\/WNL.47.6_Suppl_4.233S","article-title":"The pharmacology and mechanism of action of riluzole","volume":"47","author":"Doble","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nbd.2007.07.009","article-title":"Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6\/2 Huntington's disease mice","volume":"28","author":"Domenici","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.nbd.2008.01.015","article-title":"Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease","volume":"30","author":"Duan","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/exnr.1998.6926","article-title":"Striatal transplantation in a transgenic mouse model of Huntington's disease","volume":"154","author":"Dunnett","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib37","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1073\/pnas.1031753100","article-title":"Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo","volume":"100","author":"Erbayraktar","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib38","doi-asserted-by":"crossref","first-page":"l62","DOI":"10.1111\/j.1399-0004.1985.tb00185.x","article-title":"Diabetes mellitus in Huntington disease","volume":"27","author":"Farrer","year":"1985","journal-title":"Clin. Genet."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/mds.870110317","article-title":"Assessment of coenzyme Q10 tolerability in Huntington's disease","volume":"11","author":"Feigin","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib40","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000","article-title":"Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease","volume":"20","author":"Ferrante","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib41","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib42","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice","volume":"23","author":"Ferrante","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib43","doi-asserted-by":"crossref","first-page":"10335","DOI":"10.1523\/JNEUROSCI.2599-04.2004","article-title":"Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease","volume":"24","author":"Ferrante","year":"2004","journal-title":"J Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib44","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0014-5793(00)02380-2","article-title":"Anti-amyloidogenic activity of tetracyclines: studies in vitro","volume":"487","author":"Forloni","year":"2001","journal-title":"FEBS Lett."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib45","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1111\/j.1460-9568.2008.06310.x","article-title":"Mechanisms of neurodegeneration in Huntington's disease","volume":"27","author":"Gil","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2202-5-17","article-title":"Asialoerythropoietin is not effective in the R6\/2 line of Huntington's disease mice","volume":"5","author":"Gil","year":"2004","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib47","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.nbd.2005.05.006","article-title":"Reduced hippocampal neurogenesis in R6\/2 transgenic Huntington's disease mice","volume":"20","author":"Gil","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib48","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib49","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0306-4522(03)00595-5","article-title":"Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors","volume":"123","author":"Glass","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib50","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/6365","article-title":"Learning enhances adult neurogenesis in the hippocampal formation","volume":"2","author":"Gould","year":"1999","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib51","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1111\/j.1460-9568.2005.04365.x","article-title":"Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine","volume":"22","author":"Grote","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib52","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1096\/fasebj.13.2.411","article-title":"(R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate","volume":"13","author":"Hagen","year":"1999","journal-title":"FASEB J."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib53","doi-asserted-by":"crossref","first-page":"415","DOI":"10.18388\/abp.2004_3581","article-title":"Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease","volume":"51","author":"Hannan","year":"2004","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0006-8993(02)04275-0","article-title":"Overexpression of heat shock protein 70 in R6\/2 Huntington's disease mice has only modest effects on disease progression","volume":"970","author":"Hansson","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib55","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.1073\/pnas.110138997","article-title":"Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy","volume":"97","author":"Heiser","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib56","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1093\/hmg\/11.26.3351","article-title":"Progressive retinal degeneration and dysfunction in R6 Huntington's disease mice","volume":"11","author":"Helmlinger","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib57","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000111342","article-title":"Functional aspects of creatine kinase in brain","volume":"15","author":"Hemmer","year":"1993","journal-title":"Dev. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2005.01.024","article-title":"Early behavioral deficits in R6\/2 mice suitable for use in preclinical drug testing","volume":"20","author":"Hickey","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib59","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.10094","article-title":"Environmental enrichment slows disease progression in R6\/2 Huntington's disease mice","volume":"51","author":"Hockly","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib60","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib61","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0361-9230(03)00185-0","article-title":"Standardization and statistical approaches to therapeutic trials in the R6\/2 mouse","volume":"61","author":"Hockly","year":"2003","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib62","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.nbd.2005.07.007","article-title":"Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease","volume":"21","author":"Hockly","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib63","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1089\/hum.2006.160","article-title":"High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo","volume":"18","author":"Huang","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib64","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00221-005-2357-z","article-title":"Atypical diabetes associated with inclusion formation in the R6\/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents","volume":"166","author":"Hunt","year":"2005","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib65","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease","volume":"57","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib66","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/01.WNL.0000096019.71649.2B","article-title":"Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study","volume":"61","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib67","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1212\/01.WNL.0000133403.30559.FF","article-title":"Minocycline safety and tolerability in Huntington disease","volume":"63","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib68","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2337\/diabetes.48.3.649","article-title":"Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes","volume":"48","author":"Hurlbert","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib69","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1046\/j.1471-4159.2000.0750830.x","article-title":"Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease","volume":"75","author":"Iannicola","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib70","doi-asserted-by":"crossref","first-page":"18189","DOI":"10.1073\/pnas.0506375102","article-title":"FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease","volume":"102","author":"Jin","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib71","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/01.STR.27.2.324","article-title":"Functional outcome in rats transferred to an enriched environment 15\u00a0days after focal brain ischemia","volume":"27","author":"Johansson","year":"1996","journal-title":"Stroke"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib72","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1097-2765(00)80059-3","article-title":"Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine","volume":"1","author":"Kahlem","year":"1998","journal-title":"Mol. Cell"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib73","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm0202-143","article-title":"Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine","volume":"8","author":"Karpuj","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib74","doi-asserted-by":"crossref","first-page":"10671","DOI":"10.1073\/pnas.162362299","article-title":"Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease","volume":"99","author":"Keene","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib75","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/386493a0","article-title":"More hippocampal neurons in adult mice living in an enriched environment","volume":"386","author":"Kempermann","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib76","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1471-4159.2003.t01-1-01868.x","article-title":"Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease","volume":"86","author":"Klivenyi","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib77","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1177\/37.8.2666510","article-title":"Quantitative evaluation of Congo red binding to amyloid-like proteins with a beta-pleated sheet conformation","volume":"37","author":"Klunk","year":"1989","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib78","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.brainres.2007.04.039","article-title":"Physical activity fails to rescue hippocampal neurogenesis deficits in the R6\/2 mouse model of Huntington's disease","volume":"1155","author":"Kohl","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib79","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","article-title":"Riluzole in Huntington's disease: a 3-year, randomized controlled study","volume":"62","author":"Landwehrmeyer","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib80","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/00001756-200404090-00014","article-title":"Decreased hippocampal cell proliferation in R6\/1 Huntington's mice","volume":"15","author":"Lazic","year":"2004","journal-title":"NeuroReport"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib81","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/j.1460-9568.2006.04715.x","article-title":"Neurogenesis in the R6\/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment","volume":"23","author":"Lazic","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib82","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/hmg\/8.7.1227","article-title":"Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice","volume":"8","author":"Li","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib83","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1038\/nm1064","article-title":"Stem cell therapy for human neurodegenerative disorders\u2014how to make it work","volume":"10","author":"Lindvall","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib84","doi-asserted-by":"crossref","first-page":"10428","DOI":"10.1523\/JNEUROSCI.19-23-10428.1999","article-title":"Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation","volume":"19","author":"Lione","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib85","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0166-4328(01)00261-3","article-title":"Evaluation of R6\/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus","volume":"126","author":"Luesse","year":"2001","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib86","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/hmg\/9.9.1259","article-title":"Decreased expression of striatal signaling genes in a mouse model of Huntington's disease","volume":"9","author":"Luthi-Carter","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib87","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/hmg\/11.17.1911","article-title":"Dysregulation of gene expression in the R6\/2 model of polyglutamine disease: parallel changes in muscle and brain","volume":"11","author":"Luthi-Carter","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib88","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.nbd.2003.08.024","article-title":"Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation","volume":"14","author":"Luthi-Carter","year":"2003","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib89","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neulet.2006.10.039","article-title":"Metformin therapy in a transgenic mouse model of Huntington's disease","volume":"411","author":"Ma","year":"2007","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib90","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib91","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.cdd.4401093","article-title":"Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease","volume":"9","author":"Mastroberardino","year":"2002","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib92","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.nbd.2008.01.014","article-title":"Tiagabine is neuroprotective in the N171-82Q and R6\/2 mouse models of Huntington's disease","volume":"30","author":"Masuda","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib93","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/cne.10295","article-title":"Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6\/2 transgenic mice","volume":"449","author":"Meade","year":"2002","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib94","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1525-0016(03)00063-7","article-title":"DNA vaccination against mutant huntingtin ameliorates the HDR6\/2 diabetic phenotype","volume":"7","author":"Miller","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib95","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.neuroscience.2008.02.004","article-title":"Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6\/2 mouse","volume":"153","author":"Miller","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib96","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1460-9568.2005.03895.x","article-title":"A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease","volume":"21","author":"Morton","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib97","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1523\/JNEUROSCI.3842-04.2005","article-title":"Disintegration of the sleep\u2013wake cycle and circadian timing in Huntington's disease","volume":"25","author":"Morton","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib98","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1523\/JNEUROSCI.20-13-05115.2000","article-title":"Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease gene","volume":"20","author":"Murphy","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib99","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1073\/pnas.0502177102","article-title":"Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model","volume":"102","author":"Nguyen","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib100","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nbd.2004.07.011","article-title":"Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice","volume":"17","author":"Norflus","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib101","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/20446","article-title":"Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease","volume":"399","author":"Ona","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib102","doi-asserted-by":"crossref","first-page":"7869","DOI":"10.1523\/JNEUROSCI.0649-07.2007","article-title":"Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease","volume":"27","author":"Pallier","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib103","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1523\/JNEUROSCI.21-17-06706.2001","article-title":"Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus","volume":"21","author":"Pencea","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib104","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2007.10.015","article-title":"The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6\/2 Huntington's disease mouse model","volume":"210","author":"Peng","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib105","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1460-9568.2006.04985.x","article-title":"Hypothalamic\u2013endocrine aspects in Huntington's disease","volume":"24","author":"Peters\u00e9n","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib106","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/hmg\/ddi004","article-title":"Orexin loss in Huntington's disease","volume":"14","author":"Peters\u00e9n","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib107","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/sj.gt.3302847","article-title":"Neuroprotection by GDNF-secreting stem cells in a Huntington's disease model: optical neuroimage tracking of brain-grafted cells","volume":"14","author":"Pineda","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib108","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0140-6736(72)91092-6","article-title":"Increased frequency of diabetes mellitus in patients with Huntington's chorea","volume":"1","author":"Podolsky","year":"1972","journal-title":"Lancet"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib109","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.expneurol.2004.12.009","article-title":"Lentiviral gene delivery of GDNF into the striatum of R6\/2 Huntington mice fails to attenuate behavioral and neuropathological changes","volume":"193","author":"Popovic","year":"2005","journal-title":"Exp.Neurol."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib110","doi-asserted-by":"crossref","first-page":"RC202","DOI":"10.1523\/JNEUROSCI.22-02-j0006.2002","article-title":"Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene","volume":"22","author":"Rebec","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib111","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1097\/00001756-200307010-00015","article-title":"Ascorbate treatment attenuates the Huntington behavioral phenotype in mice","volume":"14","author":"Rebec","year":"2003","journal-title":"Neuroreport"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib112","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.neuroscience.2005.08.062","article-title":"Hyperactive striatal neurons in symptomatic Huntington R6\/2 mice: variations with behavioral state and repeated ascorbate treatment","volume":"137","author":"Rebec","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib113","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q","article-title":"Riluzole therapy in Huntington's disease (HD)","volume":"14","author":"Rosas","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib114","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/nm1066","article-title":"Protein aggregation and neurodegenerative disease","volume":"10","author":"Ross","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib115","doi-asserted-by":"crossref","first-page":"19176","DOI":"10.1073\/pnas.0606373103","article-title":"ESET\/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease","volume":"103","author":"Ryu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib116","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature01301","article-title":"Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders","volume":"421","author":"S\u00e1nchez","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib117","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brainres.2003.09.049","article-title":"Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease","volume":"994","author":"Saydoff","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib118","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.nbd.2006.08.011","article-title":"Oral uridine pro-drug PN401 is neuroprotective in the R6\/2 and N171-82Q mouse models of Huntington's disease","volume":"24","author":"Saydoff","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib119","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jacc.2003.09.050","article-title":"Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac\/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac\/DIABLO","volume":"43","author":"Scarabelli","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib120","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/mds.10229","article-title":"Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease","volume":"17","author":"Schiefer","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib121","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.brainres.2004.06.005","article-title":"The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease","volume":"1019","author":"Schiefer","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib122","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s004150170071","article-title":"Riluzole in Huntington's disease (HD): an open label study with one year follow up","volume":"248","author":"Seppi","year":"2001","journal-title":"J. Neurol."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib123","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.10614","article-title":"Minocycline and doxycycline are not beneficial in a model of Huntington's disease","volume":"54","author":"Smith","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib124","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbadis.2006.03.004","article-title":"Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice","volume":"1762","author":"Smith","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib125","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1523\/JNEUROSCI.1658-03.2004","article-title":"Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism","volume":"24","author":"Spires","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib126","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1007\/s100720200092","article-title":"CAG mutation effect on rate of progression in Huntington's disease","volume":"23","author":"Squitieri","year":"2002","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib127","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/cne.20680","article-title":"Chronology of behavioral symptoms and neuropathological sequela in R6\/2 Huntington's disease transgenic mice","volume":"490","author":"Stack","year":"2005","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib128","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbadis.2005.11.002","article-title":"Combination therapy using minocycline and coenzyme Q10 in R6\/2 transgenic Huntington's disease mice","volume":"1762","author":"Stack","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib129","doi-asserted-by":"crossref","first-page":"12908","DOI":"10.1523\/JNEUROSCI.4318-07.2007","article-title":"Neuroprotective effects of synaptic modulation in Huntington's disease R6\/2 mice","volume":"27","author":"Stack","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib130","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/hmg\/ddm064","article-title":"Modulation of nucleosome dynamics in Huntington's disease","volume":"16","author":"Stack","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib131","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib132","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nm985","article-title":"Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease","volume":"10","author":"Tanaka","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib133","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib134","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/mds.20018","article-title":"Minocycline in Huntington's disease: a pilot study","volume":"19","author":"Thomas","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib135","doi-asserted-by":"crossref","first-page":"8093","DOI":"10.1073\/pnas.110078997","article-title":"Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease","volume":"97","author":"Turmaine","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib136","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/35008142","article-title":"Delaying the onset of Huntington's in mice","volume":"404","author":"van Dellen","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib137","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0361-9230(01)00655-4","article-title":"Anterior cingulate cortical transplantation in transgenic Huntington's disease mice","volume":"56","author":"van Dellen","year":"2001","journal-title":"Brain. Res. Bull."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib138","doi-asserted-by":"crossref","first-page":"13427","DOI":"10.1073\/pnas.96.23.13427","article-title":"Running enhances neurogenesis, learning, and long-term potentiation in mice","volume":"96","author":"van Praag","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib139","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1212\/01.WNL.0000090629.40891.4B","article-title":"Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial","volume":"61","author":"Verbessem","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib140","doi-asserted-by":"crossref","first-page":"10483","DOI":"10.1073\/pnas.1832501100","article-title":"Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease","volume":"100","author":"Wang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib141","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.nbd.2005.03.026","article-title":"Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model","volume":"20","author":"Wang","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib142","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2004.12.011","article-title":"Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6\/2 mouse model of Huntington's disease","volume":"231","author":"Wang","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib143","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neures.2005.06.021","article-title":"Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA","volume":"53","author":"Wang","year":"2005","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib144","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/70532","article-title":"Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70","volume":"23","author":"Warrick","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib145","doi-asserted-by":"crossref","first-page":"9158","DOI":"10.1074\/jbc.273.15.9158","article-title":"Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract","volume":"273","author":"Wellington","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib146","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1474-4422(06)70531-2","article-title":"Predict-HD and the future of therapeutic trials","volume":"5","author":"Wild","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib147","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0361-9230(03)00141-2","article-title":"Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation","volume":"61","author":"Wood","year":"2003","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib148","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.nbd.2006.09.015","article-title":"Systemic administration of Congo red does not improve motor or cognitive function in R6\/2 mice","volume":"25","author":"Wood","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib149","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.brainresrev.2008.12.001_bib150","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/jnr.21817","article-title":"Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease","volume":"87","author":"Yang","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib151","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/7449","article-title":"Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective","volume":"5","author":"Young","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib152","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1523\/JNEUROSCI.23-06-02193.2003","article-title":"Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease","volume":"23","author":"Yu","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib153","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1046\/j.1471-4159.2003.02105.x","article-title":"Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington's disease","volume":"87","author":"Zhang","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib154","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1073\/pnas.0408936102","article-title":"A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib155","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/hmg\/ddm057","article-title":"Hsp27 overexpression in the R6\/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation","volume":"16","author":"Zourlidou","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib156","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00210-004-0959-9","article-title":"Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease","volume":"370","author":"Zucker","year":"2004","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.brainresrev.2008.12.001_bib157","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/hmg\/ddi014","article-title":"Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1","volume":"14","author":"Zucker","year":"2005","journal-title":"Hum. Mol. Genet."}],"container-title":["Brain Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165017308001392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165017308001392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T21:58:16Z","timestamp":1589407096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165017308001392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":158,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0165017308001392"],"URL":"https:\/\/doi.org\/10.1016\/j.brainresrev.2008.12.001","relation":{},"ISSN":["0165-0173"],"issn-type":[{"value":"0165-0173","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}